This study investigates advanced pancreatic cancer. The purpose of this study is to evaluate the condition using investigational medication with mFOLFIRINOX treatment.
The study evaluates the safety and effectiveness of the investigational medication in combination with mFOLFIRINOX. It focuses on overall survival, progression-free survival, and response rate.
- Who can participate: Adults aged 18 and older with advanced pancreatic cancer can participate. Participants must have measurable disease and an ECOG Performance Status of 0-1.
- Study details: Participants will receive either the investigational medication with mFOLFIRINOX or mFOLFIRINOX alone.